RELEASE: Veeva completes study migrations to Veeva Vault EDC for major biopharmaceutical company

(Information sent by the signatory company).

RELEASE: Veeva completes study migrations to Veeva Vault EDC for major biopharmaceutical company

(Information sent by the signatory company)

In an industry first, all ongoing studios migrated to Vault EDC from legacy EDC.

BARCELONA, Spain, Jan. 17, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that a top 20 biopharmaceutical company and Veeva Services have migrated 25 ongoing clinical studies to Veeva Vault EDC from a legacy capture application electronic data processing (EDC). This successful migration of an entire portfolio of core studies, including a large study with more than 500 investigational sites and 7,000 patients, is a significant industry first. Once the migrations are complete, the customer plans to use Vault EDC for all current and future testing globally.

Historically, life sciences companies have avoided migrating studies due to technical challenges, complex data models, and risk concerns. Vault EDC's patented migration capability allows Veeva Services to securely migrate ongoing studies with minimal disruption. With this top 20 biopharmaceutical company, Vault EDC was used to migrate more than 55 million data points and five million forms securely and efficiently.

“Locked legacy systems and perceived risks have made studio migration a non-starter,” said Drew Garty, CTO of Veeva Vault CDMS. "Biopharmaceutical companies can now reliably migrate ongoing studies from their legacy applications to Veeva Vault EDC with a repeatable approach that can reduce fees, drive standardization, and provide a better on-site experience."

Vault EDC's migration capability allows customers to decommission legacy EDC systems while advancing clinical data management. For more information about Vault EDC, visit

About Veeva Systems Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva serves more than 1,000 customers, from the world's largest biopharmaceutical companies to emerging biotech companies. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit

Veeva Forward-Looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from the use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we undertake no obligation to update such statements. There are numerous risks that could adversely affect our results, including the risks and uncertainties set forth in our Form 10-Q filing for the period ended October 31, 2023, which can be found here (a summary is on pages 38 and 39). of risks that may affect our business), and in our subsequent filings with the SEC, which can be accessed at

Logo -

View original content: